Rapt Therapeutics Inc.
RAPT Therapeutics Reports Second Quarter 2024 Financial Results
Summary
RAPT Therapeutics, Inc. reported financial results for the second quarter and six months ended June 30, 2024, revealing a net loss of $27.7 million for Q2 2024 compared to $25.3 million for Q2 2023. The company's total net loss for the first half of 2024 was $58.2 million. Research and development expenses increased to $22.6 million for Q2 2024, up from $21.6 million in Q2 2023, and $47.4 million for the first half of 2024. The increase was due to higher development costs for zelnecirnon and personnel expenses. On July 16, 2024, the company announced a workforce reduction affecting 47 people, with an estimated $0.9 million in restructuring charges expected to be completed by the end of Q3 2024. As of June 30, 2024, RAPT had cash and cash equivalents and marketable securities totaling $114.8 million.
Profitelligence Alerts
Get alerts for RAPT
Be first to know when Rapt Therapeutics Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Rapt Therapeutics Inc.
Rapt Therapeutics Inc. is a biotechnology firm focused on the discovery, development, and commercialization of oral small molecule therapies for oncology and inflammatory diseases. Its primary mission is to create novel treatments by harnessing its proprietary drug discovery platform, which targets key pathways responsible for the progression of these complex conditions. Rapt Therapeutics is notably advancing its development of selective inhibitors for immune checkpoint inhibitors within the broader cancer treatment landscape, potentially enhancing the efficacy of existing therapies. The company's pipeline includes multiple drug candidates tailored for specific types of cancer and chronic inflammatory disorders, underscoring its commitment to addressing unmet medical needs. By concentrating efforts on innovative approaches that modulate immune and inflammatory responses, Rapt Therapeutics plays a significant role in shaping the future of precision medicine in the biopharmaceutical industry. Founded in 2015 and leveraging advanced scientific insights, Rapt Therapeutics represents an important component of the biotech sector's efforts to push boundaries in disease treatment and improve patient outcomes.
Official SEC Documents
Advertisement